Immune Content of Mature and Licensed Cytotoxic Cells Is Associated with Treatment-Free Remission in Chronic Myeloid Leukemia

Patients with Chronic Myeloid Leukemia (CML) who achieve sustained deep molecular response (DMR) to Tyrosine Kinase Inhibitors (TKIs) are eligible for treatment discontinuation, but only 50% of those achieve long-term treatment-free remission (TFR). Current biomarkers that predict resistance to TKIs as well as loss of the molecular response after TKI interruption have not been defined. We hypothesized that antitumoral immunity mediated by Natural Killer (NK) and T cells may contribute to TFR success and result in distinct responses during treatment and after discontinuation. To explore the immune content contribution to resistance in CML, we correlated NK and T cells phenotype with BCR::ABL1 kinetics and TFR success in a cohort of CML Brazilian patients included in the DES-CML study (Study of treatment discontinuation in CML treated at the Unified Health System), a multicenter, prospective, open-label, single-arm, phase 2, non-randomized, ongoing trial, with current data from two Brazilian centers. Using multiparametric flow cytometry, we evaluated frequency, subtypes, maturation, and receptors expression of NK and T cells from diagnosis to TKI discontinuation. Peripheral blood samples from 20 healthy controls and 68 CML patients were analyzed at different time points: diagnosis (DX, N=14), Imatinib failure (F, N=13), major molecular response (MMR, N=7), DMR (N=9), TFR (N=20) and TFR loss (TFRL, N=5). Patients in the discontinuation cohort had the TKI dose reduced to 50% for 6 months before total discontinuation. NK cell subtypes were defined as secretory (CD56^brightCD16^-) or cytotoxic (CD56^dimCD16⁺). We assessed NK maturation markers (CD57 and NKp80), activation (NKG2D, NKp46 and DNAM-1), and inhibition receptors (KIR2DL1, TIGIT, NKG2A). PD-1 checkpoint inhibitor was assessed in CD8-T lymphocytes. The frequencies of cytotoxic (CD56^dim, p=0.001) and mature (CD57⁺, p=0.0078; NKp80, p=0.001) NK cells as well as activated receptors (NKG2D p=0.002; DNAM-1 p=0.0005) were lower in the DX, F, and TFRL groups as compared to patients under TKI treatment with DMR, TFR, and healthy individuals. No difference in the CD56^brigthsubtype quantification or inhibition receptors was found when those groups were compared. Patients in TFR exhibited a distinct immune profile from TFRL patients that were not influenced by gender, TKI drug, ELTS or SOKAL score. Samples from TFR patients presented higher frequency of cytotoxic (CD56^dim, p=0.001) and mature (CD57⁺, p=0.033) NK cells, and also activating receptors (NKG2D, p=0.043; DNAM-1, p=0.0002; NKp46, p=0.033) compared with TFRL. T cell frequency or CD4/CD8 subtypes did not differ between groups but PD-1 (p=0.046) and not CTLA-4 expression in T cells was decreased in TFR. At the TKI dose reduction timepoint, TFRL patients already had decreased frequency of cytotoxic (CD56^dim, p=0.0009) and mature (CD57⁺, p=0.002) NK cells as well as of the activating receptor NKG2D (p=0.0008) compared with TFR cases. Conversely, T-cell PD-1 (p=0.0302) expression was higher in TFRL than in TFR patients at the dose reduction point. In conclusion, our study indicates that impaired NK cell function and PD-1-mediated T-cell inhibition are major contributors to molecular responses in CML. Patients with sustained TFR exhibit higher frequencies of cytotoxic, mature and activated NK cells, along with lower PD-1 expression in T cells. These profile contrasts with that of patients who have persistent disease or lose molecular response post-treatment suspension, who demonstrate impaired NK cell function and increased PD-1 expression. Monitoring parameters such as mature NK content and activating receptors, particularly NKG2D, and PD-1 expression during the de-escalation phase of TKI potentially predicts TFR relapse and can be useful for decision-making.

Pagnano:Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Speakers Bureau; EMS: Research Funding; Teva: Speakers Bureau; Pintpharma: Speakers Bureau.